Qualitative study finds that both internal resources and systemic factors play a role in antipsychotic discontinuation outcomes.
A new meta-review examines the experiences of antipsychotic drugs use among people diagnosed with a psychotic disorder.
Researchers reveal the limitations and misleading interpretations of two recent studies that claim to demonstrate that long-term antipsychotic use leads to better outcomes.
The approval of the digital antipsychotic may open the door for more pharmaceutical company profits without evidence of benefits to patients.
A new study finds that adding an antipsychotic to existing antidepressant treatment is associated with a 45% increased risk of early death.
A new study has found that children and adolescents taking a high dose of antipsychotics are almost twice as likely to die of any cause than children on other types of medications.
The US Food and Drug Administration is warning the public that the antipsychotic medication ziprasidone "is associated with a rare but serious skin reaction...
A new study offers radical solutions for improving the cardiovascular health of people with mental health diagnoses: reducing antipsychotic prescriptions..
Researchers from Columbia University and other New York institutions found a dramatically increasing use of antipsychotics to treat ADHD and other behavioral problems in...
In a study of an earlier randomized controlled trial of antipsychotics, researchers from Yale and the U.K found that second-generation antipsychotics were as likely...
Members of the U.S. Food and Drug Administration’s Psychiatry Products division go on the defensive in a new article, responding to concerns about the agency’s approval of digital aripiprazole.
A new review of antipsychotic trials conducted over the last 24 years finds that the placebo response rate is steadily increasing, and drug response is decreasing.
A systematic review of the limited research available on the long-term effects of antipsychotics finds fewer symptoms in those off of the drugs.
A new study in the journal Translational Psychiatry, an influential journal in biological psychiatry published by Nature, challenges the state of the research on antipsychotic drugs.
A new study, published in the Journal of Clinical Psychiatry, investigates the effects of anticholinergic medications, such as antidepressants and antipsychotics, on cognition in older adults diagnosed with schizophrenia.
A new article in Lancet Psychiatry debunks past studies claiming that those on low doses of antipsychotics are more likely to relapse.
New study examines the experiences of people utilizing an exercise program following a first-episode psychosis.
Researchers have found further evidence that the anticholinergic effect of psychiatric drugs can lead to cognitive impairments.
The CHR-P model focuses on “attenuated psychosis” to predict “transition” to schizophrenia and ignores other factors. But new research shows that the model is a poor predictor.
Researchers developed a rating scale to better assess service users’ experiences tapering antidepressant and/or antipsychotic medication.
No placebo controlled trials provide evidence of antipsychotics in first-episode psychosis.
Researchers believe that side-effect monitoring is critical because of the increase in the use of antipsychotics
Research suggests that slowly tapering off an antipsychotic reduces the risk of withdrawal psychosis compared to abrupt discontinuation.
Antipsychotics present a known risk for major side effects. A new study suggests that certain antipsychotics may present a greater risk for cardiovascular disease than others.
Evidence of duplicate publishing in articles analyzing data from clinical trials testing second-generation antipsychotics for depression